nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.158	0.353	CbGbCtD
Trametinib—CYP2C8—Progesterone—uterine cancer	0.105	0.234	CbGbCtD
Trametinib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.064	0.143	CbGbCtD
Trametinib—CYP2C8—Etoposide—uterine cancer	0.0468	0.105	CbGbCtD
Trametinib—CYP3A4—Progesterone—uterine cancer	0.0424	0.0948	CbGbCtD
Trametinib—CYP3A4—Etoposide—uterine cancer	0.019	0.0424	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—uterine cancer	0.0129	0.0289	CbGbCtD
Trametinib—MAP2K2—myometrium—uterine cancer	0.00564	0.0775	CbGeAlD
Trametinib—MAP2K1—epithelium—uterine cancer	0.00503	0.0691	CbGeAlD
Trametinib—MAP2K1—smooth muscle tissue—uterine cancer	0.00485	0.0665	CbGeAlD
Trametinib—MAP2K1—renal system—uterine cancer	0.00467	0.0641	CbGeAlD
Trametinib—MAP2K2—uterine cervix—uterine cancer	0.00439	0.0603	CbGeAlD
Trametinib—MAP2K2—smooth muscle tissue—uterine cancer	0.00427	0.0586	CbGeAlD
Trametinib—MAP2K2—decidua—uterine cancer	0.00418	0.0574	CbGeAlD
Trametinib—MAP2K2—renal system—uterine cancer	0.00411	0.0564	CbGeAlD
Trametinib—MAP2K2—endometrium—uterine cancer	0.00397	0.0545	CbGeAlD
Trametinib—MAP2K2—mammalian vulva—uterine cancer	0.00384	0.0527	CbGeAlD
Trametinib—MAP2K1—female reproductive system—uterine cancer	0.00374	0.0513	CbGeAlD
Trametinib—MAP2K2—uterus—uterine cancer	0.00366	0.0502	CbGeAlD
Trametinib—MAP2K1—female gonad—uterine cancer	0.0034	0.0467	CbGeAlD
Trametinib—MAP2K2—female reproductive system—uterine cancer	0.00329	0.0452	CbGeAlD
Trametinib—MAP2K2—female gonad—uterine cancer	0.00299	0.0411	CbGeAlD
Trametinib—MAP2K1—lymph node—uterine cancer	0.00219	0.03	CbGeAlD
Trametinib—MAP2K2—lymph node—uterine cancer	0.00192	0.0264	CbGeAlD
Trametinib—CYP2C8—renal system—uterine cancer	0.00142	0.0195	CbGeAlD
Trametinib—CYP2C8—endometrium—uterine cancer	0.00138	0.0189	CbGeAlD
Trametinib—CYP2C8—female reproductive system—uterine cancer	0.00114	0.0156	CbGeAlD
Trametinib—CYP2C8—vagina—uterine cancer	0.00103	0.0141	CbGeAlD
Trametinib—CYP3A4—renal system—uterine cancer	0.000964	0.0132	CbGeAlD
Trametinib—CYP3A4—female reproductive system—uterine cancer	0.000772	0.0106	CbGeAlD
Trametinib—Hyperbilirubinaemia—Doxorubicin—uterine cancer	0.000414	0.00176	CcSEcCtD
Trametinib—Cellulitis—Doxorubicin—uterine cancer	0.000414	0.00176	CcSEcCtD
Trametinib—Gastrointestinal pain—Progesterone—uterine cancer	0.000414	0.00176	CcSEcCtD
Trametinib—Hypocalcaemia—Doxorubicin—uterine cancer	0.000411	0.00175	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Epirubicin—uterine cancer	0.000407	0.00173	CcSEcCtD
Trametinib—Infestation—Etoposide—uterine cancer	0.000406	0.00172	CcSEcCtD
Trametinib—Infestation NOS—Etoposide—uterine cancer	0.000406	0.00172	CcSEcCtD
Trametinib—Anaemia—Dactinomycin—uterine cancer	0.000405	0.00172	CcSEcCtD
Trametinib—Abdominal pain—Progesterone—uterine cancer	0.0004	0.0017	CcSEcCtD
Trametinib—Body temperature increased—Progesterone—uterine cancer	0.0004	0.0017	CcSEcCtD
Trametinib—Hyperkalaemia—Epirubicin—uterine cancer	0.0004	0.0017	CcSEcCtD
Trametinib—Renal failure—Etoposide—uterine cancer	0.000399	0.00169	CcSEcCtD
Trametinib—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000399	0.00169	CcSEcCtD
Trametinib—Melaena—Epirubicin—uterine cancer	0.000397	0.00169	CcSEcCtD
Trametinib—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000396	0.00168	CcSEcCtD
Trametinib—Stomatitis—Etoposide—uterine cancer	0.000396	0.00168	CcSEcCtD
Trametinib—Creatinine increased—Doxorubicin—uterine cancer	0.000395	0.00168	CcSEcCtD
Trametinib—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000395	0.00168	CcSEcCtD
Trametinib—Leukopenia—Dactinomycin—uterine cancer	0.000392	0.00167	CcSEcCtD
Trametinib—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000392	0.00167	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Doxorubicin—uterine cancer	0.000376	0.0016	CcSEcCtD
Trametinib—Dry eye—Epirubicin—uterine cancer	0.000376	0.0016	CcSEcCtD
Trametinib—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000375	0.00159	CcSEcCtD
Trametinib—Myalgia—Dactinomycin—uterine cancer	0.000373	0.00158	CcSEcCtD
Trametinib—Hyperkalaemia—Doxorubicin—uterine cancer	0.00037	0.00157	CcSEcCtD
Trametinib—Rash maculo-papular—Epirubicin—uterine cancer	0.00037	0.00157	CcSEcCtD
Trametinib—Neoplasm—Epirubicin—uterine cancer	0.000368	0.00156	CcSEcCtD
Trametinib—Mouth ulceration—Epirubicin—uterine cancer	0.000368	0.00156	CcSEcCtD
Trametinib—Melaena—Doxorubicin—uterine cancer	0.000368	0.00156	CcSEcCtD
Trametinib—Asthenia—Progesterone—uterine cancer	0.000363	0.00154	CcSEcCtD
Trametinib—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000363	0.00154	CcSEcCtD
Trametinib—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000363	0.00154	CcSEcCtD
Trametinib—Urinary tract disorder—Etoposide—uterine cancer	0.00036	0.00153	CcSEcCtD
Trametinib—Pruritus—Progesterone—uterine cancer	0.000358	0.00152	CcSEcCtD
Trametinib—Oedema—Dactinomycin—uterine cancer	0.000358	0.00152	CcSEcCtD
Trametinib—Urethral disorder—Etoposide—uterine cancer	0.000357	0.00152	CcSEcCtD
Trametinib—Infection—Dactinomycin—uterine cancer	0.000355	0.00151	CcSEcCtD
Trametinib—Thrombocytopenia—Dactinomycin—uterine cancer	0.00035	0.00149	CcSEcCtD
Trametinib—Dry eye—Doxorubicin—uterine cancer	0.000348	0.00148	CcSEcCtD
Trametinib—Diarrhoea—Progesterone—uterine cancer	0.000346	0.00147	CcSEcCtD
Trametinib—Rash maculo-papular—Doxorubicin—uterine cancer	0.000342	0.00145	CcSEcCtD
Trametinib—Eye disorder—Etoposide—uterine cancer	0.000341	0.00145	CcSEcCtD
Trametinib—Neoplasm—Doxorubicin—uterine cancer	0.00034	0.00145	CcSEcCtD
Trametinib—Mouth ulceration—Doxorubicin—uterine cancer	0.00034	0.00145	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	0.00034	0.00144	CcSEcCtD
Trametinib—Cardiac disorder—Etoposide—uterine cancer	0.000338	0.00144	CcSEcCtD
Trametinib—Dizziness—Progesterone—uterine cancer	0.000335	0.00142	CcSEcCtD
Trametinib—Angiopathy—Etoposide—uterine cancer	0.000331	0.0014	CcSEcCtD
Trametinib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000329	0.0014	CcSEcCtD
Trametinib—Mediastinal disorder—Etoposide—uterine cancer	0.000329	0.00139	CcSEcCtD
Trametinib—Chills—Etoposide—uterine cancer	0.000327	0.00139	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000326	0.00138	CcSEcCtD
Trametinib—Cardiac failure congestive—Epirubicin—uterine cancer	0.000326	0.00138	CcSEcCtD
Trametinib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000325	0.00138	CcSEcCtD
Trametinib—Vomiting—Progesterone—uterine cancer	0.000322	0.00137	CcSEcCtD
Trametinib—Renal failure acute—Epirubicin—uterine cancer	0.00032	0.00136	CcSEcCtD
Trametinib—Rash—Progesterone—uterine cancer	0.000319	0.00136	CcSEcCtD
Trametinib—Dermatitis—Progesterone—uterine cancer	0.000319	0.00135	CcSEcCtD
Trametinib—Headache—Progesterone—uterine cancer	0.000317	0.00135	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000314	0.00133	CcSEcCtD
Trametinib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000314	0.00133	CcSEcCtD
Trametinib—Decreased appetite—Dactinomycin—uterine cancer	0.000311	0.00132	CcSEcCtD
Trametinib—Dysgeusia—Etoposide—uterine cancer	0.000311	0.00132	CcSEcCtD
Trametinib—Fatigue—Dactinomycin—uterine cancer	0.000308	0.00131	CcSEcCtD
Trametinib—Back pain—Etoposide—uterine cancer	0.000307	0.0013	CcSEcCtD
Trametinib—Muscle spasms—Etoposide—uterine cancer	0.000305	0.0013	CcSEcCtD
Trametinib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000303	0.00129	CcSEcCtD
Trametinib—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000301	0.00128	CcSEcCtD
Trametinib—Nausea—Progesterone—uterine cancer	0.000301	0.00128	CcSEcCtD
Trametinib—Hyponatraemia—Epirubicin—uterine cancer	0.000297	0.00126	CcSEcCtD
Trametinib—Renal failure acute—Doxorubicin—uterine cancer	0.000296	0.00126	CcSEcCtD
Trametinib—Pain in extremity—Epirubicin—uterine cancer	0.000295	0.00125	CcSEcCtD
Trametinib—Anaemia—Etoposide—uterine cancer	0.000293	0.00125	CcSEcCtD
Trametinib—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000293	0.00124	CcSEcCtD
Trametinib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000292	0.00124	CcSEcCtD
Trametinib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000289	0.00123	CcSEcCtD
Trametinib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000289	0.00123	CcSEcCtD
Trametinib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000287	0.00122	CcSEcCtD
Trametinib—Leukopenia—Etoposide—uterine cancer	0.000284	0.00121	CcSEcCtD
Trametinib—Abdominal pain—Dactinomycin—uterine cancer	0.000283	0.0012	CcSEcCtD
Trametinib—Body temperature increased—Dactinomycin—uterine cancer	0.000283	0.0012	CcSEcCtD
Trametinib—Cough—Etoposide—uterine cancer	0.000277	0.00118	CcSEcCtD
Trametinib—Blood creatinine increased—Epirubicin—uterine cancer	0.000277	0.00117	CcSEcCtD
Trametinib—Dehydration—Epirubicin—uterine cancer	0.000275	0.00117	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—uterine cancer	0.000274	0.00116	CcSEcCtD
Trametinib—Hypertension—Etoposide—uterine cancer	0.000274	0.00116	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—uterine cancer	0.000273	0.00116	CcSEcCtD
Trametinib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000272	0.00116	CcSEcCtD
Trametinib—Dry skin—Epirubicin—uterine cancer	0.000271	0.00115	CcSEcCtD
Trametinib—Abdominal pain upper—Epirubicin—uterine cancer	0.00027	0.00115	CcSEcCtD
Trametinib—Hypokalaemia—Epirubicin—uterine cancer	0.000269	0.00114	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000268	0.00114	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000266	0.00113	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.00026	0.00111	CcSEcCtD
Trametinib—Infection—Etoposide—uterine cancer	0.000257	0.00109	CcSEcCtD
Trametinib—Asthenia—Dactinomycin—uterine cancer	0.000257	0.00109	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—uterine cancer	0.000256	0.00109	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—uterine cancer	0.000254	0.00108	CcSEcCtD
Trametinib—Thrombocytopenia—Etoposide—uterine cancer	0.000254	0.00108	CcSEcCtD
Trametinib—Skin disorder—Etoposide—uterine cancer	0.000252	0.00107	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—uterine cancer	0.00025	0.00106	CcSEcCtD
Trametinib—Hyperhidrosis—Etoposide—uterine cancer	0.00025	0.00106	CcSEcCtD
Trametinib—Pancreatitis—Epirubicin—uterine cancer	0.00025	0.00106	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—uterine cancer	0.00025	0.00106	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—uterine cancer	0.000249	0.00106	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000246	0.00104	CcSEcCtD
Trametinib—Diarrhoea—Dactinomycin—uterine cancer	0.000245	0.00104	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000241	0.00102	CcSEcCtD
Trametinib—Neutropenia—Epirubicin—uterine cancer	0.000239	0.00101	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—uterine cancer	0.000232	0.000983	CcSEcCtD
Trametinib—Hyperglycaemia—Epirubicin—uterine cancer	0.00023	0.000978	CcSEcCtD
Trametinib—Infestation—Epirubicin—uterine cancer	0.000228	0.000966	CcSEcCtD
Trametinib—Infestation NOS—Epirubicin—uterine cancer	0.000228	0.000966	CcSEcCtD
Trametinib—Vomiting—Dactinomycin—uterine cancer	0.000227	0.000966	CcSEcCtD
Trametinib—Rash—Dactinomycin—uterine cancer	0.000226	0.000958	CcSEcCtD
Trametinib—Decreased appetite—Etoposide—uterine cancer	0.000225	0.000956	CcSEcCtD
Trametinib—Renal failure—Epirubicin—uterine cancer	0.000224	0.00095	CcSEcCtD
Trametinib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000224	0.000949	CcSEcCtD
Trametinib—Fatigue—Etoposide—uterine cancer	0.000223	0.000948	CcSEcCtD
Trametinib—Stomatitis—Epirubicin—uterine cancer	0.000222	0.000942	CcSEcCtD
Trametinib—Constipation—Etoposide—uterine cancer	0.000221	0.00094	CcSEcCtD
Trametinib—Urinary tract infection—Epirubicin—uterine cancer	0.000221	0.000939	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—uterine cancer	0.000221	0.000938	CcSEcCtD
Trametinib—Haematuria—Epirubicin—uterine cancer	0.000217	0.000921	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—uterine cancer	0.000215	0.000911	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—uterine cancer	0.000213	0.000905	CcSEcCtD
Trametinib—Nausea—Dactinomycin—uterine cancer	0.000213	0.000902	CcSEcCtD
Trametinib—Gastrointestinal pain—Etoposide—uterine cancer	0.000212	0.000899	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—uterine cancer	0.000211	0.000894	CcSEcCtD
Trametinib—Infestation—Doxorubicin—uterine cancer	0.000211	0.000894	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—uterine cancer	0.000208	0.000883	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—uterine cancer	0.000207	0.000879	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—uterine cancer	0.000205	0.000872	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—uterine cancer	0.000205	0.000871	CcSEcCtD
Trametinib—Body temperature increased—Etoposide—uterine cancer	0.000205	0.000869	CcSEcCtD
Trametinib—Abdominal pain—Etoposide—uterine cancer	0.000205	0.000869	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—uterine cancer	0.000205	0.000869	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—uterine cancer	0.000204	0.000867	CcSEcCtD
Trametinib—Urinary tract disorder—Epirubicin—uterine cancer	0.000202	0.000857	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—uterine cancer	0.000201	0.000855	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—uterine cancer	0.000201	0.000852	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—uterine cancer	0.000201	0.000852	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—uterine cancer	0.0002	0.00085	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—uterine cancer	0.000199	0.000843	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—uterine cancer	0.000192	0.000817	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—uterine cancer	0.000191	0.000811	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—uterine cancer	0.00019	0.000807	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—uterine cancer	0.00019	0.000805	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—uterine cancer	0.000189	0.000803	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—uterine cancer	0.000187	0.000793	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—uterine cancer	0.000186	0.000791	CcSEcCtD
Trametinib—Asthenia—Etoposide—uterine cancer	0.000186	0.000789	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—uterine cancer	0.000186	0.000789	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—uterine cancer	0.000185	0.000787	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—uterine cancer	0.000185	0.000787	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—uterine cancer	0.000184	0.000782	CcSEcCtD
Trametinib—Chills—Epirubicin—uterine cancer	0.000183	0.000778	CcSEcCtD
Trametinib—Pruritus—Etoposide—uterine cancer	0.000183	0.000778	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—uterine cancer	0.000183	0.000775	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—uterine cancer	0.000179	0.00076	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—uterine cancer	0.000178	0.000755	CcSEcCtD
Trametinib—Erythema—Epirubicin—uterine cancer	0.000178	0.000755	CcSEcCtD
Trametinib—Diarrhoea—Etoposide—uterine cancer	0.000177	0.000752	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—uterine cancer	0.000177	0.00075	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—uterine cancer	0.000175	0.000745	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—uterine cancer	0.000174	0.000739	CcSEcCtD
Trametinib—Back pain—Epirubicin—uterine cancer	0.000172	0.00073	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—uterine cancer	0.000172	0.000728	CcSEcCtD
Trametinib—Dizziness—Etoposide—uterine cancer	0.000171	0.000727	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—uterine cancer	0.000171	0.000726	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—uterine cancer	0.00017	0.000723	CcSEcCtD
Trametinib—Chills—Doxorubicin—uterine cancer	0.00017	0.00072	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—uterine cancer	0.000169	0.000717	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—uterine cancer	0.000168	0.000712	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—uterine cancer	0.000166	0.000703	CcSEcCtD
Trametinib—Vomiting—Etoposide—uterine cancer	0.000165	0.000699	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—uterine cancer	0.000165	0.000699	CcSEcCtD
Trametinib—Erythema—Doxorubicin—uterine cancer	0.000165	0.000699	CcSEcCtD
Trametinib—Anaemia—Epirubicin—uterine cancer	0.000164	0.000698	CcSEcCtD
Trametinib—Rash—Etoposide—uterine cancer	0.000163	0.000693	CcSEcCtD
Trametinib—Dermatitis—Etoposide—uterine cancer	0.000163	0.000693	CcSEcCtD
Trametinib—Headache—Etoposide—uterine cancer	0.000162	0.000689	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—uterine cancer	0.000161	0.000684	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—uterine cancer	0.000159	0.000676	CcSEcCtD
Trametinib—Back pain—Doxorubicin—uterine cancer	0.000159	0.000676	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—uterine cancer	0.000158	0.000672	CcSEcCtD
Trametinib—Cough—Epirubicin—uterine cancer	0.000155	0.000659	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—uterine cancer	0.000155	0.000658	CcSEcCtD
Trametinib—Nausea—Etoposide—uterine cancer	0.000154	0.000653	CcSEcCtD
Trametinib—Hypertension—Epirubicin—uterine cancer	0.000154	0.000652	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—uterine cancer	0.000152	0.000646	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—uterine cancer	0.000151	0.000643	CcSEcCtD
Trametinib—Myalgia—Epirubicin—uterine cancer	0.000151	0.000643	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.00015	0.000638	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—uterine cancer	0.000148	0.000629	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—uterine cancer	0.000147	0.000625	CcSEcCtD
Trametinib—Oedema—Epirubicin—uterine cancer	0.000145	0.000616	CcSEcCtD
Trametinib—Infection—Epirubicin—uterine cancer	0.000144	0.000612	CcSEcCtD
Trametinib—Cough—Doxorubicin—uterine cancer	0.000144	0.00061	CcSEcCtD
Trametinib—Nervous system disorder—Epirubicin—uterine cancer	0.000142	0.000604	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—uterine cancer	0.000142	0.000603	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—uterine cancer	0.000142	0.000603	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—uterine cancer	0.000141	0.000599	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—uterine cancer	0.00014	0.000596	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—uterine cancer	0.00014	0.000595	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—uterine cancer	0.00014	0.000595	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000139	0.000591	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—uterine cancer	0.000137	0.000582	CcSEcCtD
Trametinib—Oedema—Doxorubicin—uterine cancer	0.000134	0.00057	CcSEcCtD
Trametinib—Infection—Doxorubicin—uterine cancer	0.000133	0.000566	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000132	0.000561	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—uterine cancer	0.000132	0.000559	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—uterine cancer	0.000132	0.000558	CcSEcCtD
Trametinib—Insomnia—Epirubicin—uterine cancer	0.000131	0.000557	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—uterine cancer	0.00013	0.000554	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—uterine cancer	0.00013	0.000551	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—uterine cancer	0.000126	0.000536	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000125	0.000532	CcSEcCtD
Trametinib—Fatigue—Epirubicin—uterine cancer	0.000125	0.000531	CcSEcCtD
Trametinib—Constipation—Epirubicin—uterine cancer	0.000124	0.000527	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000122	0.00052	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—uterine cancer	0.000121	0.000516	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—uterine cancer	0.000119	0.000504	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—uterine cancer	0.000117	0.000496	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000116	0.000492	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—uterine cancer	0.000116	0.000492	CcSEcCtD
Trametinib—Constipation—Doxorubicin—uterine cancer	0.000115	0.000488	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—uterine cancer	0.000115	0.000487	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—uterine cancer	0.000115	0.000487	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—uterine cancer	0.00011	0.000466	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—uterine cancer	0.000106	0.000451	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—uterine cancer	0.000106	0.000451	CcSEcCtD
Trametinib—Asthenia—Epirubicin—uterine cancer	0.000104	0.000442	CcSEcCtD
Trametinib—Pruritus—Epirubicin—uterine cancer	0.000103	0.000436	CcSEcCtD
Trametinib—Diarrhoea—Epirubicin—uterine cancer	9.93e-05	0.000422	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—uterine cancer	9.64e-05	0.000409	CcSEcCtD
Trametinib—Dizziness—Epirubicin—uterine cancer	9.6e-05	0.000408	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—uterine cancer	9.5e-05	0.000403	CcSEcCtD
Trametinib—Vomiting—Epirubicin—uterine cancer	9.23e-05	0.000392	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—uterine cancer	9.19e-05	0.00039	CcSEcCtD
Trametinib—Rash—Epirubicin—uterine cancer	9.15e-05	0.000389	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—uterine cancer	9.14e-05	0.000388	CcSEcCtD
Trametinib—Headache—Epirubicin—uterine cancer	9.09e-05	0.000386	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—uterine cancer	8.88e-05	0.000377	CcSEcCtD
Trametinib—Nausea—Epirubicin—uterine cancer	8.62e-05	0.000366	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—uterine cancer	8.54e-05	0.000363	CcSEcCtD
Trametinib—Rash—Doxorubicin—uterine cancer	8.47e-05	0.00036	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—uterine cancer	8.46e-05	0.000359	CcSEcCtD
Trametinib—Headache—Doxorubicin—uterine cancer	8.41e-05	0.000357	CcSEcCtD
Trametinib—Nausea—Doxorubicin—uterine cancer	7.98e-05	0.000339	CcSEcCtD
Trametinib—MAP2K1—Insulin Signaling—AKT1—uterine cancer	5.54e-05	0.000227	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKR1C1—uterine cancer	5.53e-05	0.000227	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—AKT1—uterine cancer	5.51e-05	0.000226	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—FBXW7—uterine cancer	5.49e-05	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—AKT1—uterine cancer	5.49e-05	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—AKT1—uterine cancer	5.49e-05	0.000225	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—NRAS—uterine cancer	5.48e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—HRAS—uterine cancer	5.48e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—HRAS—uterine cancer	5.47e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—AKT1—uterine cancer	5.46e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—AKT1—uterine cancer	5.46e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—AKT1—uterine cancer	5.46e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—AKT1—uterine cancer	5.46e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—AKT1—uterine cancer	5.43e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K2—Disease—FBXW7—uterine cancer	5.42e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—AKT1—uterine cancer	5.41e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—NRAS—uterine cancer	5.39e-05	0.000221	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	5.38e-05	0.00022	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—AKT1—uterine cancer	5.37e-05	0.00022	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	5.36e-05	0.000219	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—AKT1—uterine cancer	5.34e-05	0.000219	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—AKT1—uterine cancer	5.33e-05	0.000218	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	5.3e-05	0.000217	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—VEGFA—uterine cancer	5.28e-05	0.000216	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—NRAS—uterine cancer	5.21e-05	0.000214	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKR1C1—uterine cancer	5.18e-05	0.000212	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—AKT1—uterine cancer	5.16e-05	0.000211	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—HRAS—uterine cancer	5.13e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—AKT1—uterine cancer	5.11e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—AKT1—uterine cancer	5.11e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—AKT1—uterine cancer	5.11e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FBXW7—uterine cancer	5.07e-05	0.000208	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—AKT1—uterine cancer	5.07e-05	0.000207	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—KRAS—uterine cancer	5.04e-05	0.000207	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—AKT1—uterine cancer	5.02e-05	0.000206	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—AKT1—uterine cancer	5e-05	0.000205	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—KRAS—uterine cancer	4.96e-05	0.000203	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	4.96e-05	0.000203	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—VEGFA—uterine cancer	4.94e-05	0.000202	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—ERBB2—uterine cancer	4.89e-05	0.0002	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—NRAS—uterine cancer	4.88e-05	0.0002	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	4.84e-05	0.000198	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—AKT1—uterine cancer	4.83e-05	0.000198	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	4.81e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—SOCS3—uterine cancer	4.81e-05	0.000197	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—KRAS—uterine cancer	4.72e-05	0.000193	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—KRAS—uterine cancer	4.64e-05	0.00019	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	4.63e-05	0.00019	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—ERBB2—uterine cancer	4.58e-05	0.000187	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—PIK3CA—uterine cancer	4.56e-05	0.000187	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	4.53e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—SOCS3—uterine cancer	4.5e-05	0.000184	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—KRAS—uterine cancer	4.49e-05	0.000184	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	4.34e-05	0.000178	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—ERBB2—uterine cancer	4.32e-05	0.000177	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HRAS—uterine cancer	4.29e-05	0.000176	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—CTNNB1—uterine cancer	4.28e-05	0.000175	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—PIK3CA—uterine cancer	4.26e-05	0.000175	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKR1C3—uterine cancer	4.26e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN2B—uterine cancer	4.25e-05	0.000174	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—STAR—uterine cancer	4.24e-05	0.000174	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKR1B1—uterine cancer	4.24e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—HRAS—uterine cancer	4.22e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—KRAS—uterine cancer	4.2e-05	0.000172	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	4.2e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PGR—uterine cancer	4.15e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—ERBB2—uterine cancer	4.04e-05	0.000165	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HRAS—uterine cancer	4.01e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—FGFR2—uterine cancer	4.01e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CTNNB1—uterine cancer	4e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CDKN1B—uterine cancer	4e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKR1C3—uterine cancer	3.98e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EP300—uterine cancer	3.98e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN2B—uterine cancer	3.97e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—YWHAE—uterine cancer	3.96e-05	0.000162	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—HRAS—uterine cancer	3.94e-05	0.000161	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PGR—uterine cancer	3.88e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SMAD3—uterine cancer	3.88e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—HRAS—uterine cancer	3.82e-05	0.000156	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FBXW7—uterine cancer	3.8e-05	0.000155	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CTNNB1—uterine cancer	3.78e-05	0.000155	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—VEGFA—uterine cancer	3.77e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—FGFR2—uterine cancer	3.75e-05	0.000153	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CDKN1B—uterine cancer	3.74e-05	0.000153	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—AKT1—uterine cancer	3.72e-05	0.000152	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EP300—uterine cancer	3.72e-05	0.000152	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—NRAS—uterine cancer	3.72e-05	0.000152	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—YWHAE—uterine cancer	3.7e-05	0.000152	CbGpPWpGaD
Trametinib—MAP2K2—Disease—FGFR2—uterine cancer	3.7e-05	0.000151	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PTEN—uterine cancer	3.68e-05	0.000151	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SMAD3—uterine cancer	3.63e-05	0.000149	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—HRAS—uterine cancer	3.57e-05	0.000146	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MTHFR—uterine cancer	3.56e-05	0.000146	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FBXW7—uterine cancer	3.55e-05	0.000145	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CTNNB1—uterine cancer	3.54e-05	0.000145	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—uterine cancer	3.52e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EP300—uterine cancer	3.51e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—AKT1—uterine cancer	3.48e-05	0.000143	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NRAS—uterine cancer	3.48e-05	0.000143	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FGFR2—uterine cancer	3.46e-05	0.000142	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PTEN—uterine cancer	3.45e-05	0.000141	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MTHFR—uterine cancer	3.33e-05	0.000136	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—POLD1—uterine cancer	3.33e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STK11—uterine cancer	3.32e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CCL2—uterine cancer	3.3e-05	0.000135	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EP300—uterine cancer	3.29e-05	0.000135	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—NRAS—uterine cancer	3.29e-05	0.000135	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—KRAS—uterine cancer	3.2e-05	0.000131	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NDUFB11—uterine cancer	3.15e-05	0.000129	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SRD5A2—uterine cancer	3.15e-05	0.000129	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKR1C1—uterine cancer	3.12e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SOCS3—uterine cancer	3.11e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STK11—uterine cancer	3.1e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CCL2—uterine cancer	3.09e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NRAS—uterine cancer	3.07e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KRAS—uterine cancer	3e-05	0.000123	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDH1—uterine cancer	2.98e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN2B—uterine cancer	2.97e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SOCS3—uterine cancer	2.91e-05	0.000119	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1R—uterine cancer	2.89e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KRAS—uterine cancer	2.83e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDH1—uterine cancer	2.79e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN2B—uterine cancer	2.78e-05	0.000114	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—RRM2—uterine cancer	2.78e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HRAS—uterine cancer	2.72e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SMAD3—uterine cancer	2.72e-05	0.000111	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1R—uterine cancer	2.7e-05	0.000111	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—DCN—uterine cancer	2.7e-05	0.00011	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KRAS—uterine cancer	2.65e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL8—uterine cancer	2.61e-05	0.000107	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PIK3CA—uterine cancer	2.6e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGFR2—uterine cancer	2.59e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HRAS—uterine cancer	2.55e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SMAD3—uterine cancer	2.54e-05	0.000104	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP11A1—uterine cancer	2.54e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ERBB2—uterine cancer	2.52e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL8—uterine cancer	2.44e-05	0.0001	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PIK3CA—uterine cancer	2.43e-05	9.95e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGFR2—uterine cancer	2.42e-05	9.92e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—uterine cancer	2.4e-05	9.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—uterine cancer	2.4e-05	9.84e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKR1C3—uterine cancer	2.4e-05	9.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ERBB2—uterine cancer	2.35e-05	9.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDKN1B—uterine cancer	2.33e-05	9.54e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB2—uterine cancer	2.32e-05	9.51e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKR1B1—uterine cancer	2.28e-05	9.33e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—STAR—uterine cancer	2.28e-05	9.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—uterine cancer	2.25e-05	9.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—uterine cancer	2.25e-05	9.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ESR1—uterine cancer	2.22e-05	9.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CTNNB1—uterine cancer	2.2e-05	9.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1B—uterine cancer	2.18e-05	8.93e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB2—uterine cancer	2.17e-05	8.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1B—uterine cancer	2.15e-05	8.81e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—uterine cancer	2.15e-05	8.78e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—uterine cancer	2.12e-05	8.69e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—uterine cancer	2.09e-05	8.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ESR1—uterine cancer	2.07e-05	8.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—uterine cancer	2.06e-05	8.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EP300—uterine cancer	2.05e-05	8.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—uterine cancer	2.03e-05	8.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1B—uterine cancer	2.01e-05	8.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—uterine cancer	2.01e-05	8.22e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—uterine cancer	1.99e-05	8.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—uterine cancer	1.98e-05	8.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—uterine cancer	1.96e-05	8.02e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCL2—uterine cancer	1.95e-05	7.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EP300—uterine cancer	1.91e-05	7.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—uterine cancer	1.91e-05	7.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—uterine cancer	1.9e-05	7.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EP300—uterine cancer	1.89e-05	7.73e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP19A1—uterine cancer	1.87e-05	7.65e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—STK11—uterine cancer	1.87e-05	7.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—uterine cancer	1.85e-05	7.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCL2—uterine cancer	1.83e-05	7.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—uterine cancer	1.8e-05	7.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—uterine cancer	1.79e-05	7.33e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—POLD1—uterine cancer	1.79e-05	7.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EP300—uterine cancer	1.77e-05	7.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—uterine cancer	1.77e-05	7.24e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.75e-05	7.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—uterine cancer	1.69e-05	6.91e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.67e-05	6.85e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.67e-05	6.85e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—uterine cancer	1.66e-05	6.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—uterine cancer	1.65e-05	6.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—uterine cancer	1.65e-05	6.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—uterine cancer	1.63e-05	6.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—uterine cancer	1.55e-05	6.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—uterine cancer	1.54e-05	6.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—uterine cancer	1.54e-05	6.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—uterine cancer	1.53e-05	6.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—uterine cancer	1.52e-05	6.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—uterine cancer	1.52e-05	6.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—uterine cancer	1.51e-05	6.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1B—uterine cancer	1.51e-05	6.17e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—RRM2—uterine cancer	1.49e-05	6.1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—DCN—uterine cancer	1.45e-05	5.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—uterine cancer	1.44e-05	5.91e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—uterine cancer	1.43e-05	5.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—uterine cancer	1.42e-05	5.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—uterine cancer	1.42e-05	5.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—uterine cancer	1.42e-05	5.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1B—uterine cancer	1.41e-05	5.77e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MTHFR—uterine cancer	1.4e-05	5.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—uterine cancer	1.4e-05	5.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—uterine cancer	1.4e-05	5.72e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—uterine cancer	1.39e-05	5.68e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.36e-05	5.58e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—uterine cancer	1.35e-05	5.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—uterine cancer	1.33e-05	5.45e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EP300—uterine cancer	1.32e-05	5.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—uterine cancer	1.31e-05	5.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—uterine cancer	1.31e-05	5.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—uterine cancer	1.3e-05	5.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—uterine cancer	1.29e-05	5.29e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.29e-05	5.27e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—uterine cancer	1.27e-05	5.18e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—uterine cancer	1.25e-05	5.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EP300—uterine cancer	1.24e-05	5.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—uterine cancer	1.24e-05	5.07e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.24e-05	5.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—uterine cancer	1.24e-05	5.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—uterine cancer	1.21e-05	4.95e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—uterine cancer	1.17e-05	4.8e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—uterine cancer	1.16e-05	4.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—uterine cancer	1.16e-05	4.74e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—uterine cancer	1.14e-05	4.67e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—uterine cancer	1.07e-05	4.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—uterine cancer	1.07e-05	4.36e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—STK11—uterine cancer	1e-05	4.11e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	1e-05	4.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—uterine cancer	9.97e-06	4.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—uterine cancer	9.79e-06	4.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—uterine cancer	9.47e-06	3.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—uterine cancer	9.16e-06	3.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—uterine cancer	9.05e-06	3.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—uterine cancer	8.86e-06	3.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—uterine cancer	8.47e-06	3.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—uterine cancer	7.99e-06	3.27e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—uterine cancer	7.81e-06	3.2e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTHFR—uterine cancer	7.54e-06	3.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—uterine cancer	7.48e-06	3.06e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—EP300—uterine cancer	7.45e-06	3.05e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—uterine cancer	5.51e-06	2.26e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—uterine cancer	4.5e-06	1.84e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—uterine cancer	4.19e-06	1.72e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—EP300—uterine cancer	4e-06	1.64e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	2.96e-06	1.21e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—uterine cancer	2.42e-06	9.89e-06	CbGpPWpGaD
